In rosacea, a single treatment may not be enough.
Dr. Harper offered these other pearls to consider when treating rosacea:
* Don't get hung up on subtypes.
The four subtypes of rosacea should be used to classify lesions, not people, she said. That's because patients can fall into more than one of the four categories --erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea, she noted.
"Document the redness you see and ask them what's bothering them the most," she said. And ask yourself, she added, "Do I have them on everything that I should have them on?"
* Talk to patients about triggers.
For the first visit, "we have to talk to patients about skin care and triggers," Dr. Harper noted. According to the American Academy of Dermatology, common rosacea triggers include sunlight, hairspray, heat, stress, alcohol, and spicy foods.
* Consider an ivermectin-brimonidine combination.
"Targeting inflammation in papules and pustules doesn't necessarily translate to less background erythema," Dr. Harper said. What to do? She pointed to a 2017 study that examined a combination treatment of ivermectin 1% topical cream (Soolantra) and brimonidine 0.33% topical gel (Mirvaso) for patients with rosacea with moderate to severe persistent erythema and inflammatory lesions. Ivermectin is indicated for inflammatory lesions, while brimonidine treats persistent erythema. At week 12, the proportion of patients who achieved investigator global assessment of clear or almost clear was 55.8% in the combination group, versus 36.8% of those in the vehicle group (P = .007), according to the study (J Drugs Dermatol. 2017 Sep 1;16:909-16). Dr. Harper highlighted the effect of brimonidine when added to ivermectin. "In a period of 3 hours," she said, "we had twice as many people fall into clear or almost clear."
* Consider adding botulinum toxin to your toolbox.
This "really does work," Dr. Harper said. She pointed to a 2015 report of botulinum toxin use in two cases of refractory flushing and erythema and a 2012 report of 13 cases in patients with the same symptoms (Dermatology. 2015;230:299-301; J Drugs Dermatol. 2012 Dec;ll:e76-9). Dr. Harper said that she usually uses the full 50-unit dose of Botox.
* Consider a beta-blocker.
According to a 2018 report, the beta-blocker carvedilol (Coreg) showed benefit when added to other treatments in five patients with facial flushing and persistent erythema.
* Keep isotretinoin in mind.
A 2016 report suggested low-dose isotretinoin had value for difficult-to-treat papulopustular rosacea. As Dr. Harper noted, 57% of those who took isotretinoin reached the primary endpoint, versus 10% of those taking the placebo. However, relapses over 4 months were common, which is a sign that it may be wise to prescribe low doses over the long term, but not in females of child-bearing potential, she said.
The Coastal Dermatology Symposium is jointly presented by the University of Louisville and Global Academy for Medical Education. This publication and Global Academy for Medical Education are both owned by Frontline Medical Communications.
Dr. Harper disclosed speaker/adviser relationships with Allergan, Bayer, BioPharmX, Galderma, LaRoche Posay and Ortho and has served as investigator for Bayer.
BY RANDY DOTINGA
EXPERT ANALYSIS FROM THE COASTAL DERMATOLOGY SYMPOSIUM
Caption: Dr. Harper
Caption: The four subtypes of rosacea should be used to classify lesions, not people, because patients can fall into more than one of the four categories.
Please Note: Illustration(s) are not available due to copyright restrictions.
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Nov 1, 2018|
|Previous Article:||Allergen of the year may be nearer than you think.|
|Next Article:||Nononbstructive angina? Do acetylcholine test.|